FILANA THERAPEUTICS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$95.4M | -$141.4M | -$106.0M | -$80.0M | -$32.9M |
| Operating expenses | $95.4M | $141.4M | $106.0M | $80.0M | $32.9M |
| Cash from operations | -$32.3M | -$116.9M | -$82.0M | -$77.5M | -$30.2M |
| Capital expenditure | $581,000 | $103,000 | $414,000 | $2.7M | $22.2M |
| Free cash flow | -$32.8M | -$117.0M | -$82.4M | -$80.2M | -$52.4M |
| Total assets | $118.4M | $157.5M | $151.7M | $234.8M | $266.8M |
| Total liabilities | $44.0M | $11.8M | $14.2M | $7.3M | $12.9M |
Shares outstanding 48.3M · Free float 87.9%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.